FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Edward Kim

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Tumor Cell Line

Physiology

Mutation

Co-author Network

Publications

TOP 3
James W Welsh; Erik Sulman; Wyatt Unger; Jeffrey S Wefel; Pamela K Allen; Arya Amini; Paul Brown; Joe Y Chang; Su S Chen; Linda L Garland; John V Heymach; Jamie Holt; Edward S Kim; Ritsuko Komaki; Zhongxing Liao; Susan L McGovern; Mark F Munsell; Baldassarre Stea
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
William N William; Ignacio I Wistuba; Arlene M Correa; Jeremy J Erasmus; Kathryn A Gold; John Heymach; Neda Kalhor; Edward S Kim; J Jack Lee; Reginald F Munden; Vassiliki A Papadimitrakopoulou; Abujiang Pataer; David C Rice; Stephen G Swisher
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
Humam Kadara; Edward S Kim; Wenhua Lang; J Jack Lee; Diane A Liu; Li Mao; Pierre Saintigny; Li Shen; Jing Wang; Carmen Behrens; Chi-Wan Chow; Zuoming Chu; Kevin R Coombes; You-Hong Fan; Junya Fujimoto; Melinda Garcia; Kathryn A Gold; Waun Ki Hong; Mohamed Kabbout; Ignacio I Wistuba
Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Edward Kim (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: James W Welsh; Erik Sulman; Wyatt Unger; Jeffrey S Wefel; Pamela K Allen; Arya Amini; Paul Brown; Joe Y Chang; Su S Chen; Linda L Garland; John V Heymach; Jamie Holt; Edward S Kim; Ritsuko Komaki; Zhongxing Liao; Susan L McGovern; Mark F Munsell; Baldassarre Stea
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(7):895-902.
2013: William N William; Ignacio I Wistuba; Arlene M Correa; Jeremy J Erasmus; Kathryn A Gold; John Heymach; Neda Kalhor; Edward S Kim; J Jack Lee; Reginald F Munden; Vassiliki A Papadimitrakopoulou; Abujiang Pataer; David C Rice; Stephen G Swisher
Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013;8(2):222-8.
2013: Humam Kadara; Edward S Kim; Wenhua Lang; J Jack Lee; Diane A Liu; Li Mao; Pierre Saintigny; Li Shen; Jing Wang; Carmen Behrens; Chi-Wan Chow; Zuoming Chu; Kevin R Coombes; You-Hong Fan; Junya Fujimoto; Melinda Garcia; Kathryn A Gold; Waun Ki Hong; Mohamed Kabbout; Ignacio I Wistuba
Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling.
Cancer prevention research (Philadelphia, Pa.) 2013;6(1):8-17.
2013: Kathryn A Gold; Edward S Kim; Ignacio I Wistuba; Waun K Hong
Personalizing lung cancer prevention through a reverse migration strategy.
Topics in current chemistry 2013;329():221-40.
2012: Woo-Young Kim; Lei Feng; Bonnie Glisson; Bryan Hennessy; Waun Ki Hong; Edward S Kim; J Jack Lee; Ju Seog Lee; Scott M Lippman; Ludmila Prudkin; Ignacio I Wistuba; Ho-Young Lee
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
Cancer 2012;118(16):3993-4003.
2012: Caleb T Chu; Yvonne H Sada; Edward S Kim
Vandetanib for the treatment of lung cancer.
Expert opinion on investigational drugs 2012;21(8):1211-21.
2012: Seung Hyun Oh; Ok-Hee Lee; Ju-Hee Kang; Edward S Kim; Jong Kyu Woo; Ho-Young Lee
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
International journal of cancer. Journal international du cancer 2012;131(3):537-47.
2012: Kathryn A Gold; Ignacio I Wistuba; Edward S Kim
New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(11):3002-7.
2012: Xiaoying Liu; John Minna; Jack A Roth; Stephen G Swisher; Ji Wang; Li Wang; Michael Wang; Shuhong Wu; Luc Girard; Wei Guo; John V Heymach; Edward S Kim; Bingbing Dai; Bingliang Fang
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells.
Biochemical pharmacology 2012;83(10):1456-64.
2012: Abujiang Pataer; Maria Gabriela Raso; Jack A Roth; David J Stewart; Stephen G Swisher; Ara A Vaporciyan; Ignacio I Wistuba; Carmen Behrens; Arlene M Correa; Jeremy J Erasmus; Neda Kalhor; Edward S Kim; J Jack Lee
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(5):825-32.
2012: Jin-Soo Kim; Carmen Behrens; Waun Ki Hong; Edward S Kim; J Jack Lee; Scott M Lippman; Diane Liu; Luisa Solis; Ignacio I Wistuba; Ho-Young Lee
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer.
Cancer 2012;118(9):2454-65.
2012: Nathan T Ihle; Edward S Kim; Jill E Larsen; J Jack Lee; Scott M Lippman; Suyu Liu; John D Minna; Vassiliki A Papadimitrakopoulou; Mena F Abdelmelek; George R Blumenschein; Lauren A Byers; Lu Chen; Kevin R Coombes; Lixia Diao; Roy S Herbst; John V Heymach; Waun K Hong; Pierre Saintigny; Ximing Tang; Anne Tsao; Jing Wang; Ignacio I Wistuba; Shuxing Zhang; Garth Powis
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Journal of the National Cancer Institute 2012;104(3):228-39.
2011: Jangsoon Lee; Seung-Hee Ryu; Wen-Cheng Chung; Kathryn Ann Gold; Walter N Hittelman; Shin Myung Kang; Waun Ki Hong; Edward S Kim; Ja Seok Koo
Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.
Cancer prevention research (Philadelphia, Pa.) 2011;4(8):1306-15.
2011: Kathryn A Gold; Edward S Kim; J Jack Lee; Ignacio I Wistuba; Carol J Farhangfar; Waun Ki Hong
The BATTLE to personalize lung cancer prevention through reverse migration.
Cancer prevention research (Philadelphia, Pa.) 2011;4(7):962-72.
2011: Edith M Marom; Miguel A Milito; Cesar A Moran; David C Rice; Arlene M Correa; Jeremy J Erasmus; Wayne L Hofstetter; Edward S Kim; Ritsuko Komaki; Ping Liu; Stephen G Swisher
Computed tomography findings predicting invasiveness of thymoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(7):1274-81.
2011: Hai T Tran; Ralph G Zinner; George R Blumenschein; Yun W Oh; Vassiliki A Papadimitrakopoulou; Edward S Kim; Charles Lu; Mubashira Malik; Bert L Lum; Roy S Herbst
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Investigational new drugs 2011;29(3):499-505.
2011: Alda Tam; Prachee Singh; Joe Ensor; Kristina Carter; Edward S Kim; Marshall E Hicks; Michael J Wallace; Sanjay Gupta
Air travel after biopsy-related pneumothorax: is it safe to fly?
Journal of vascular and interventional radiology : JVIR 2011;22(5):595-602.e1.
2010: Roy S Herbst; Karen Kelly; Kari Chansky; Philip C Mack; Wilbur A Franklin; Fred R Hirsch; James N Atkins; Shaker R Dakhil; Kathy S Albain; Edward S Kim; Mary Redman; John J Crowley; David R Gandara
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4747-54.
2010: Margaret Em Van Meter; Edward S Kim
Bevacizumab: current updates in treatment.
Current opinion in oncology 2010;22(6):586-91.
2010: Pierre Saintigny; Ignacio I Wistuba; Edward S Kim
Bronchioloalveolar carcinoma: a translational perspective.
Oncology (Williston Park, N.Y.) 2010;24(10):907-8, 914.
2010: William N William; Merrill S Kies; Frank V Fossella; Diane D Liu; Gregory W Gladish; Warner H Tse; J Jack Lee; Waun K Hong; Scott M Lippman; Edward S Kim
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
Cancer 2010;116(10):2401-8.
2010: William N William; Fadlo R Khuri; Frank V Fossella; Bonnie S Glisson; Ralph G Zinner; J Jack Lee; Roy S Herbst; Scott M Lippman; Edward S Kim
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
American journal of clinical oncology 2010;33(2):148-52.
2010: Zhongxing X Liao; Ritsuko R Komaki; Howard D Thames; Helen H Liu; Susan L Tucker; Radhe Mohan; Mary K Martel; Xiong Wei; Kunyu Yang; Edward S Kim; George Blumenschein; Waun Ki Hong; James D Cox
Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy.
International journal of radiation oncology, biology, physics 2010;76(3):775-81.
2010: Jean-Yves Douillard; Frances A Shepherd; Vera Hirsh; Tony Shu Kam Mok; Mark A Socinski; Radj Gervais; Mei-Lin Liao; Helge Bischoff; Martin Reck; Mark V Sellers; Claire L Watkins; Georgina Speake; Alison A Armour; Edward S Kim
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):744-52.
2010: Edward S Kim; Waun K Hong; J Jack Lee; Li Mao; Rodolfo C Morice; Diane D Liu; Carlos A Jimenez; Georgie A Eapen; Reuben Lotan; Ximing Tang; Robert A Newman; Ignacio I Wistuba; Jonathan M Kurie
Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
Cancer prevention research (Philadelphia, Pa.) 2010;3(2):148-59.
2010: Emer O Hanrahan; Heather Y Lin; Edward S Kim; Shaoyu Yan; Danny Z Du; Kathryn S McKee; Hai T Tran; J Jack Lee; Anderson Ryan; Peter Langmuir; Bruce E Johnson; John V Heymach
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(2):193-201.
2009: Pierre Saintigny; Adel K El-Naggar; Vassiliki A Papadimitrakopoulou; Hening Ren; You-Hong Fan; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Scott M Lippman; Li Mao
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6284-91.
2009: Woo-Young Kim; Quanri Jin; Seung-Hyun Oh; Edward S Kim; Youn Joo Yang; Dong Hoon Lee; Lei Feng; Carmen Behrens; Ludmila Prudkin; York E Miller; J Jack Lee; Scott M Lippman; Waun Ki Hong; Ignacio I Wistuba; Ho-Young Lee
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development.
Cancer research 2009;69(18):7439-48.
2009: William N William; Heather Y Lin; J Jack Lee; Scott M Lippman; Jack A Roth; Edward S Kim
Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data.
Chest 2009;136(3):701-9.
2009: Emer O Hanrahan; Merrill S Kies; Bonnie S Glisson; Fadlo R Khuri; Lei Feng; Hai T Tran; Lawrence E Ginsberg; Mylene T Truong; Waun K Hong; Edward S Kim
A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.
American journal of clinical oncology 2009;32(3):274-9.
2009: Kathryn A Gold; Edward S Kim
Role of molecular markers and gene profiling in head and neck cancers.
Current opinion in oncology 2009;21(3):206-11.
2009: Edward S Kim; Ann M Mauer; William N William; Hai T Tran; Diane Liu; Jack J Lee; Paul Windt; Waun Ki Hong; Everett E Vokes; Roy S Herbst
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.
Cancer 2009;115(8):1713-22.
2009: William N William; John V Heymach; Edward S Kim; Scott M Lippman
Molecular targets for cancer chemoprevention.
Nature reviews. Drug discovery 2009;8(3):213-25.
2009: William N William; Edward S Kim; Roy S Herbst
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck.
Nature clinical practice. Oncology 2009;6(3):132-3.
2009: Kathryn A Gold; Ho-Young Lee; Edward S Kim
Targeted therapies in squamous cell carcinoma of the head and neck.
Cancer 2009;115(5):922-35.
2009: William N William; Joseph L Lee; Dong M Shin; Waun Ki Hong; Suyu Liu; J Jack Lee; Scott M Lippman; Fadlo R Khuri; Edward S Kim
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.
American journal of clinical oncology 2009;32(1):15-9.
2009: Vassiliki A Papadimitrakopoulou; J Jack Lee; William N William; Jack W Martin; Margaret Thomas; Edward S Kim; Fadlo R Khuri; Dong M Shin; Lei Feng; Waun Ki Hong; Scott M Lippman
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):599-604.
2009: William N William; J Jack Lee; Scott M Lippman; Jack W Martin; Nitin Chakravarti; Hai T Tran; Anita L Sabichi; Edward S Kim; Lei Feng; Reuben Lotan; Vassiliki A Papadimitrakopoulou
High-dose fenretinide in oral leukoplakia.
Cancer prevention research (Philadelphia, Pa.) 2009;2(1):22-6.
2008: Edward S Kim; Vera Hirsh; Tony Shu Kam Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; Long-yun Li; Claire L Watkins; Mark V Sellers; Elizabeth S Lowe; Yan Sun; Mei-Lin Liao; Kell Osterlind; Martin Reck; Alison A Armour; Frances A Shepherd; Scott M Lippman; Jean-Yves Douillard
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Lancet 2008;372(9652):1809-18.
2008: Manisha Bhutani; Ashutosh Kumar Pathak; You-Hong Fan; Diane D Liu; J Jack Lee; Hongli Tang; Jonathan M Kurie; Rodolfo C Morice; Edward S Kim; Waun Ki Hong; Li Mao
Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs.
Cancer prevention research (Philadelphia, Pa.) 2008;1(1):39-44.
2008: Seung Hyun Oh; Quanri Jin; Edward S Kim; Fadlo R Khuri; Ho-Young Lee
Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(5):1581-9.
2007: Floriana Morgillo; Woo-Young Kim; Edward S Kim; Fortunato Ciardiello; Waun Ki Hong; Ho-Young Lee
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2795-803.
2006: Floriana Morgillo; Jong K Woo; Edward S Kim; Waun Ki Hong; Ho-Young Lee
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Cancer research 2006;66(20):10100-11.
2006: Fadlo R Khuri; J Jack Lee; Scott M Lippman; Edward S Kim; Jay S Cooper; Steven E Benner; Rodger Winn; Thomas F Pajak; Brendell Williams; George Shenouda; Ian Hodson; Karen Fu; Dong M Shin; Everett E Vokes; Lei Feng; Helmuth Goepfert; Waun Ki Hong
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
Journal of the National Cancer Institute 2006;98(7):441-50.
2005: Edward S Kim; Ewan D Johnson
Novel combinations with docetaxel in the treatment of non-small-cell lung cancer.
Clinical lung cancer 2005;7 Suppl 3():S83-6.
2005: Ralph G Zinner; Frank V Fossella; Gregory W Gladish; Bonnie S Glisson; George R Blumenschein; Vassiliki A Papadimitrakopoulou; Katherine M W Pisters; Edward S Kim; Yun W Oh; Beverly O Peeples; Zhishen Ye; Rafael E Curiel; Coleman K Obasaju; Waun Ki Hong; Roy S Herbst
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
Cancer 2005;104(11):2449-56.
2005: Edward S Kim; Merrill S Kies; Frank V Fossella; Bonnie S Glisson; Sara Zaknoen; Paul Statkevich; Reginald F Munden; Carmen Summey; Katherine M W Pisters; Vassiliki A Papadimitrakopoulou; Mourad Tighiouart; André Rogatko; Fadlo R Khuri
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Cancer 2005;104(3):561-9.
2005: Phuong Khanh H Morrow; Edward S Kim
New biological agents in the treatment of advanced non-small cell lung cancer.
Seminars in respiratory and critical care medicine 2005;26(3):323-32.
2005: Roy S Herbst; David H Johnson; Eric Mininberg; David P Carbone; Ted Henderson; Edward S Kim; George R Blumenschein; Jack J Lee; Diane D Liu; Mylene T Truong; Waun Ki Hong; Hai Tran; Anne S Tsao; Dong Xie; David A Ramies; Robert Mass; Somasekar Seshagiri; David A Eberhard; Sean K Kelley; Alan B Sandler
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(11):2544-55.
2004: Edward S Kim
Cetuximab as a single agent or in combination with chemotherapy in lung cancer.
Clinical lung cancer 2004;6 Suppl 2():S80-4.
2004: Luo Wang; Marivonne Rodriguez; Edward S Kim; Yunling Xu; Neby Bekele; Adel K El-Naggar; Waun Ki Hong; Li Mao; Yun W Oh
A novel C/T polymorphism in the core promoter of human de novo cytosine DNA methyltransferase 3B6 is associated with prognosis in head and neck cancer.
International journal of oncology 2004;25(4):993-9.
2004: Edward S Kim; Joe B Putnam; Ritsuko Komaki; Garrett L Walsh; Jae Y Ro; Hyung Ju Shin; Mylene T Truong; Hojin Moon; Stephen G Swisher; Frank V Fossella; Fadlo R Khuri; Waun Ki Hong; Dong M Shin
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
Lung cancer (Amsterdam, Netherlands) 2004;44(3):369-79.
2004: Anne S Tsao; Edward S Kim; Waun Ki Hong
Chemoprevention of cancer.
CA: a cancer journal for clinicians 2004;54(3):150-80.
2004: Fadlo R Khuri; Bonnie S Glisson; Edward S Kim; Paul Statkevich; Peter F Thall; Michael L Meyers; Roy S Herbst; Reginald F Munden; Craig Tendler; Yali Zhu; Sandra Bangert; Elizabeth Thompson; Charles Lu; Xue-Mei Wang; Dong M Shin; Merrill S Kies; Vassiliki A Papadimitrakopoulou; Frank V Fossella; Paul Kirschmeier; W Robert Bishop; Waun Ki Hong
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2968-76.
2004: Edward S Kim; Everett E Vokes; Merrill S Kies
Cetuximab in cancers of the lung and head & neck.
Seminars in oncology 2004;31(1 Suppl 1):61-7.
2003: Edward S Kim
Epidermal growth factor receptor as a target in cancer therapy.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1 Suppl 1():S87-95.
2003: Edward S Kim; Bonnie S Glisson
Treatment of metastatic head and neck cancer: chemotherapy and novel agents.
Cancer treatment and research 2003;114():295-314.
2002: Edward S Kim; Fadlo R Khuri
Chemoprevention of lung cancer.
Current oncology reports 2002;4(4):341-6.
2002: Edward S Kim; Roy S Herbst
Angiogenesis inhibitors in lung cancer.
Current oncology reports 2002;4(4):325-33.
2002: Edward S Kim; Fadlo R Khuri
Docetaxel and radiation as combined-modality therapy.
Oncology (Williston Park, N.Y.) 2002;16(6 Suppl 6):97-105.
2002: Edward S Kim; Merrill S Kies; Roy S Herbst
Novel therapeutics for head and neck cancer.
Current opinion in oncology 2002;14(3):334-42.
2002: Erminia Massarelli; Amir Onn; Ralph G Zinner; Fadlo R Khuri; Edward S Kim; Roy S Herbst
New targets for the treatment of advanced non-small cell lung cancer.
Cancer chemotherapy and biological response modifiers 2002;20():717-61.
2002: Edward S Kim; Waun Ki Hong; Fadlo R Khuri
Chemoprevention of aerodigestive tract cancers.
Annual review of medicine 2002;53():223-43.
2001: Edward S Kim; C Lu; Fadlo R Khuri; M Tonda; Bonnie S Glisson; D Liu; M Jung; Waun Ki Hong; Roy S Herbst
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;34(3):427-32.
2001: Edward S Kim; Fadlo R Khuri; Roy S Herbst
Epidermal growth factor receptor biology (IMC-C225).
Current opinion in oncology 2001;13(6):506-13.
2001: Fadlo R Khuri; Edward S Kim; J Jack Lee; RJ Winn; Steven E Benner; Scott M Lippman; Karen K Fu; Jay S Cooper; Everett E Vokes; Robert M Chamberlain; Brendell Williams; Thomas F Pajak; Helmuth Goepfert; Waun Ki Hong
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(8):823-9.
2000: Edward S Kim; Waun Ki Hong; Fadlo R Khuri
Prevention of lung cancer. The new millennium.
Chest surgery clinics of North America 2000;10(4):663-90, v.
1999: Pamarthi M Mohan; Chintala Shravan; Sanjeeva Mohanam; CL Gladson; Edward S Kim; Ziya L Gokaslan; Seeta Sajani Lakka; Jack A Roth; Bingliang Fang; Raymond Sawaya; Athanassios P Kyritsis; Jasti Sambasiva Rao
Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth.
Cancer research 1999;59(14):3369-73.